80.74

1.44% -1.18

Cytokinetics Inc (CYTK)

Overview News Price History Option Chain Financials Why CYTK Down? Discussions Forecast Stock Split

Cytokinetics Inc stock is traded at $80.74, with a volume of 1.85M. It is down -1.44% in the last 24 hours and down -0.57% over the past month. Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Previous Close:

$81.92

Open:

$82.59

24h Volume:

1.85M

Relative Volume:

0.73

Market Cap:

$10.96B

Revenue:

$105.82M

Net Income/Loss:

$-829.61M

P/E Ratio:

-11.80

EPS:

-6.8429

Net Cash Flow:

$-548.92M

1W Performance:

+0.70%

1M Performance:

-0.57%

6M Performance:

+27.33%

1Y Performance:

+116.40%

1-Day Range:

$80.28

$82.59

1-Week Range:

$78.81

$83.83

52-Week Range:

$32.89

$88.31

Cytokinetics Inc Stock (CYTK) Company Profile

Name

Cytokinetics Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

(650) 624-3000

Address

350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Employee

673

Twitter

@Cytokinetics

Next Earnings Date

2026-08-06

Latest SEC Filings

CYTK's Discussions on Twitter

Compare CYTK vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CYTK Cytokinetics Inc	80.74	10.96B	105.82M	-829.61M	-548.92M	-6.8429
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Wells Fargo	Overweight
Jan-28-26	Resumed	Barclays	Overweight
Dec-18-25	Upgrade	Goldman	Neutral → Buy
Jul-30-25	Resumed	Raymond James	Mkt Perform
Apr-24-25	Initiated	Barclays	Overweight
Feb-07-25	Initiated	Citigroup	Buy
Jan-22-25	Initiated	Stifel	Buy
Nov-08-24	Initiated	RBC Capital Mkts	Outperform
Aug-13-24	Downgrade	Goldman	Buy → Neutral
Jan-24-24	Downgrade	UBS	Buy → Neutral
Jan-05-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-23	Initiated	Goldman	Buy
Nov-07-23	Initiated	B. Riley Securities	Buy
Aug-15-23	Initiated	SVB Securities	Outperform
Feb-17-23	Initiated	BofA Securities	Neutral
Dec-23-22	Reiterated	Needham	Buy
Dec-20-22	Initiated	Truist	Buy
Oct-11-22	Initiated	UBS	Buy
Jan-28-22	Initiated	Goldman	Buy
Dec-22-21	Initiated	Oppenheimer	Outperform
Dec-10-21	Initiated	JP Morgan	Overweight
Oct-07-21	Initiated	Jefferies	Buy
Mar-12-21	Initiated	Wolfe Research	Outperform
Feb-18-21	Initiated	Barclays	Overweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-29-20	Initiated	Goldman	Neutral
Jul-10-20	Initiated	Raymond James	Strong Buy
May-05-20	Initiated	Mizuho	Buy
Apr-09-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-10-18	Resumed	Morgan Stanley	Equal-Weight
Nov-22-17	Reiterated	Morgan Stanley	Overweight
Nov-22-17	Downgrade	Needham	Strong Buy → Buy
Nov-21-17	Reiterated	H.C. Wainwright	Buy
Jul-31-17	Initiated	Morgan Stanley	Overweight
Mar-08-17	Initiated	Rodman & Renshaw	Buy
Feb-06-17	Upgrade	Needham	Buy → Strong Buy
Dec-16-16	Initiated	Cantor Fitzgerald	Overweight
Jul-28-16	Reiterated	Needham	Buy
Nov-10-15	Reiterated	FBR Capital	Outperform
Nov-09-15	Reiterated	ROTH Capital	Buy
Jul-24-15	Reiterated	MLV & Co	Buy
Dec-31-14	Reiterated	ROTH Capital	Buy
Nov-04-14	Upgrade	MLV & Co	Hold → Buy
Apr-28-14	Reiterated	Needham	Buy

View All

Cytokinetics Inc Stock (CYTK) Latest News

Jul 24, 2026

Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada

Jul 24, 2026

Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada

Jul 24, 2026

Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance UK

Jul 24, 2026

Form 4 Cytokinetics Inc For: 24 July By Investing.com - Investing.com South Africa

Jul 24, 2026

Cytokinetics EVP Fady Malik sells $282,065 in company stock - Investing.com

Jul 24, 2026

Jul 23, 2026

Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus

Jul 23, 2026

Cytokinetics Insider Sold Shares Worth $282,065, According to a Recent SEC Filing - marketscreener.com

Jul 23, 2026

Cytokinetics to Announce Second Quarter Results on August 6, 2026 - The Manila Times

Jul 23, 2026

Cytokinetics Will Share Q2 Results Aug. 6, Then Host Live Call - Stock Titan

Jul 23, 2026

Cytokinetics to Announce Second Quarter Results on August 6, 2026 - GlobeNewswire Inc.

Jul 23, 2026

CYTK stock holds recent gains as Cytokinetics prepares next heart failure data readout - AD HOC NEWS

Jul 23, 2026

Jul 22, 2026

Cytokinetics, Incorporated (CYTK) Options Chain - Yahoo! Finance Canada

Jul 22, 2026

Cytokinetics: Label Expansion Can Turn MYQORZO Into An HCM Franchise (NASDAQ:CYTK) - Seeking Alpha

Jul 22, 2026

Jul 21, 2026

Cytokinetics CEO on the launch of its first commercial drug - Yahoo Finance

Jul 21, 2026

Jul 19, 2026

Cytokinetics stock edges higher as cardiovascular pipeline and cash position underpin outlook - Ad-hoc-news.de

Jul 19, 2026

Jul 17, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 17, 2026

New Cytokinetics hires receive stock awards with 3- and 4-year vesting - Stock Titan

Jul 17, 2026

Citi Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $99 - Moomoo

Jul 17, 2026

Jul 16, 2026

Form 4 Cytokinetics Inc For: 16 July By Investing.com - Investing.com Nigeria

Jul 16, 2026

Cytokinetics (CYTK) director Nancy Wysenski granted 75 fully vested shares - Stock Titan

Jul 16, 2026

Director stock grant at Cytokinetics (CYTK) highlights equity retainer - Stock Titan

Jul 16, 2026

Cytokinetics (CYTK) awards 151-share fully vested grant to director - Stock Titan

Jul 16, 2026